DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2012/0301400 A1 Williams Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2012/0301400 A1 Williams Et Al US 201203 01400A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0301400 A1 Williams et al. (43) Pub. Date: Nov. 29, 2012 (54) MEDITOPES AND MEDITOPE-BINDING (30) Foreign Application Priority Data ANTIBODIES AND USES THEREOF Oct. 10, 2011 (US) ................. PCT/US2011/055656 (76) Inventors: John C. Williams, Monrovia, CA (US); David A. Horne, Duarte, CA Publication Classification (US); Yuelong Ma, Duarte, CA (51) Int. Cl. (US); Heng Wei Chang, Foster C07K 6/8 (2006.01) City, CA (US); Joshua Michael C07K 7/08 (2006.01) Donaldson, Lumberton, NJ (US); C07K L/4 (2006.01) Cindy Zer, Duarte, CA (US); A 6LX 39/395 (2006.01) Krzysztof Bzymek, Pasadena, CA A61R 49/00 (2006.01) (US); Kendra Nicole Avery, CI2N 5/071 (2010.01) Pasadena, CA (US); Jun Xie, C07K 7/06 (2006.01) Duarte, CA (US) C07K 2/00 (2006.01) (21) Appl. No.: 13/443,804 (52) U.S. Cl. ....... 424/9.1; 530/387.9; 530/330,530/329; 530/328; 530/327: 530/326; 530/321; 424/139.1; (22) Filed: Apr. 10, 2012 424/178.1; 435/331 Related U.S. Application Data (57) ABSTRACT (63) Continuation-in-part of application No. 13/270.207, Antibodies and meditopes that bind to the antibodies are filed on Oct. 10, 2011. provided, as well as complexes, compositions and combina (60) Provisional application No. 61/391,558, filed on Oct. tions containing the meditopes and antibodies, and methods 8, 2010, provisional application No. 61/597,708, filed of producing, using, testing, and screening the same, includ on Feb. 10, 2012. ing therapeutic and diagnostic methods and uses. Patent Application Publication Nov. 29, 2012 Sheet 1 of 79 US 2012/0301400 A1 figure i Patent Application Publication Nov. 29, 2012 Sheet 2 of 79 US 2012/0301400 A1 *igi: 3. A. :::::::::: 8. Patent Application Publication Nov. 29, 2012 Sheet 3 of 79 US 2012/0301400 A1 *igars: 3 3. 2 ao 12o so zoo 8 s 8x 8 i co YN o O 5. Patent Application Publication Nov. 29, 2012 Sheet 4 of 79 US 2012/0301400 A1 ra. 8 & ::: :::: $3:::::::::::: 38:3. 8:xxx: :::::::::::::::::::::::::::: 88:38 C :38: Patent Application Publication Nov. 29, 2012 Sheet 5 of 79 US 2012/0301400 A1 Figs: i. ER ti :::: W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W. W.r ::..: 3. sEx*x: 8 Patent Application Publication Nov. 29, 2012 Sheet 6 of 79 US 2012/0301400 A1 Eigases isotype Control Patent Application Publication Nov. 29, 2012 Sheet 7 of 79 US 2012/0301400 A1 *igare is ::::::: Meditope Patent Application Publication Nov. 29, 2012 Sheet 8 of 79 US 2012/0301400 A1 Eigtse editope Patent Application Publication Nov. 29, 2012 Sheet 9 of 79 US 2012/0301400 A1 Figure 8 Tumor Cell . Multivalent Meditope Tumor Antigen Antibody i i i "Daisy Chained" nati N. ff f ( , ) is 4. it:Recitope vil--- - - - - D Patent Application Publication Nov. 29, 2012 Sheet 10 of 79 US 2012/0301400 A1 Eigtse at variabieight chain a variabie heavy chair Patent Application Publication Nov. 29, 2012 Sheet 11 of 79 US 2012/0301400 A1 Patent Application Publication Nov. 29, 2012 Sheet 12 of 79 US 2012/0301400 A1 figure it unior Association Protease Site & Fabv. N-te it is 88 f Patent Application Publication Nov. 29, 2012 Sheet 13 of 79 US 2012/0301400 A1 first-gwaient tecitope ferawaient editope : s & & &. 8 8 : Patent Application Publication Nov. 29, 2012 Sheet 15 of 79 US 2012/0301400 A1 $igare is Patent Application Publication Nov. 29, 2012 Sheet 16 of 79 US 2012/0301400 A1 if 2 x is Expected xw: 858,8328 Patent Application Publication Nov. 29, 2012 Sheet 17 of 79 US 2012/0301400 A1 figske is 8x:it:8-8: S: 3883:388xie: 3:3: 388 S: 3:38; $ 8:8: 8::::: Patent Application Publication Nov. 29, 2012 Sheet 18 of 79 US 2012/0301400 A1 iigake ié ex Patent Application Publication Nov. 29, 2012 Sheet 19 of 79 US 2012/0301400 A1 8:38 8:3888 .x: s :--------------------&- Patent Application Publication Nov. 29, 2012 Sheet 20 of 79 US 2012/0301400 A1 iigare i8 *:: *egios: Patent Application Publication Nov. 29, 2012 Sheet 21 of 79 US 2012/0301400 A1 Big:: i: ''.------- A. W ''''''''':------''. Patent Application Publication Nov. 29, 2012 Sheet 22 of 79 US 2012/0301400 A1 exex x. x : y : xxx ... xxxxx x xxxx xxx xxxx Patent Application Publication Nov. 29, 2012 Sheet 23 of 79 US 2012/0301400 A1 *igare 3. 8 8 Patent Application Publication Nov. 29, 2012 Sheet 24 of 79 US 2012/0301400 A1 Eigtse 2: 3 : x 8Kxitxx-xxxxix. $88:28:888 ; : x 8xxii:gk-xxxxix. 8:28: : xi xiii-xx: 888:28:8: s ; :x: 8xxiii-xx-xxxix. 888::::::::::::: is xi xiii-xx: 8888.88: Patent Application Publication Nov. 29, 2012 Sheet 25 of 79 US 2012/0301400 A1 S : s 8. Patent Application Publication Nov. 29, 2012 Sheet 26 of 79 US 2012/0301400 A1 *igare 336 & Patent Application Publication Nov. 29, 2012 Sheet 27 of 79 US 2012/0301400 A1 $igi: 33 3. 8. { ai: -ier2. CDR-graft At | 3pm Her2 CDR-graft mAh is tier2. CDR-graft mat 2: 1 M Trastuzumab 1. So YYYYYYmemrol Negative Cotro: 8 $3 3 t Aexa $4 trait + 3 um Meditope-Fc O at hier2. CDR-graft mAh 3 Mier2. CDR-graft rab Mier2. CDR-graft rab Mirastuzurnal Negative Contro: so to: : to Aixa 88 editage Patent Application Publication Nov. 29, 2012 Sheet 28 of 79 US 2012/0301400 A1 8 Patent Application Publication Nov. 29, 2012 Sheet 29 of 79 US 2012/0301400 A1 Patent Application Publication Nov. 29, 2012 Sheet 30 of 79 US 2012/0301400 A1 Patent Application Publication Nov. 29, 2012 Sheet 31 of 79 US 2012/0301400 A1 al Patent Application Publication Nov. 29, 2012 Sheet 32 of 79 US 2012/0301400 A1 s8 s s s s s s 8 kettskira: a responser : 8 & www.www. 3.288 83.8:8 38: exitxpe. 8 8-32: Patent Application Publication Nov. 29, 2012 Sheet 33 of 79 US 2012/0301400 A1 Eig:e 3: Cetixia Bixing 8: kitixia Nix biaxiing 8stiga: No riding Patent Application Publication Nov. 29, 2012 Sheet 34 of 79 US 2012/0301400 A1 Rigxixe 38& Patent Application Publication Nov. 29, 2012 Sheet 35 of 79 US 2012/0301400 A1 iigare i8 8.8 xi. : x : 3. 8: : : :: x Patent Application Publication Nov. 29, 2012 Sheet 36 of 79 US 2012/0301400 A1 Figare 386. Patent Application Publication Nov. 29, 2012 Sheet 37 of 79 US 2012/0301400 A1 Eigare 31E Seq # 2 15 18 31 32 33 3 : Patent Application Publication Nov. 29, 2012 Sheet 38 of 79 US 2012/0301400 A1 Figure 3i ^ ''. i&ii ( , -i. r Patent Application Publication Nov. 29, 2012 Sheet 39 of 79 US 2012/0301400 A1 Figare 33 , starriercise: Fric g88 &y8xxis. V. ... 88&xxxix8; 8-cellstretx i. i* {&g:FES$88.K: ; : 3, 2. {&: 3. *::Fixx.‘ $.8xxxxxxxxixe: 8888 &:. 3:33. 8:38. Patent Application Publication Nov. 29, 2012 Sheet 40 of 79 US 2012/0301400 A1 Ki ir-in- - - Ki-ir 8xxiified Arg8 R Kaiky, skixstituted aikyi, arratic 3 -i-8" 8:388 8' x axy, sixstitutex &ikyi, a extratic Patent Application Publication Nov. 29, 2012 Sheet 41 of 79 US 2012/0301400 A1 *igars 35 Patent Application Publication Nov. 29, 2012 Sheet 42 of 79 US 2012/0301400 A1 Patent Application Publication Nov. 29, 2012 Sheet 43 of 79 US 2012/0301400 A1 case eperties initition of cetaxirat iteractix with itxesceir-aixiexi epixie isy triaxeied eptide : 8 8s s :--, & & & SS 8 &: 8 8w & x & Patent Application Publication Nov. 29, 2012 Sheet 44 of 79 US 2012/0301400 A1 Sigt: 38 Patent Application Publication Nov. 29, 2012 Sheet 45 of 79 US 2012/0301400 A1 iigare: s 8. Patent Application Publication Nov. 29, 2012 Sheet 46 of 79 US 2012/0301400 A1 is:ge 3: 88i is 3: 3. Patent Application Publication Nov. 29, 2012 Sheet 47 of 79 US 2012/0301400 A1 Figare 39 est's : ki Patent Application Publication Nov. 29, 2012 Sheet 48 of 79 US 2012/0301400 A1 s Patent Application Publication Nov. 29, 2012 Sheet 49 of 79 US 2012/0301400 A1 Fig.: 3 xxxiii Patent Application Publication Nov. 29, 2012 Sheet 57 of 79 US 2012/0301400 A1 figure it extti Set is is: s: 88: 3ta. Exieties 8x838 -8:3 *::::: 8:::, 83.88 83.88, &.88, 88.88, x: 883 883.x: :. g . 833, 8:..., xx. 38.3, 8.3, 83.3 Resortior: } 33.88.8.3: 3:.83.38: 838-3.88: 3.8-3.8 3.x: x. 88.8 x8:888% 88.88. 88.8 88.8 8x3x38:y 8.- : 38 888 3.83; efiteest 888xxiii.388: 3.x: 8:3. ::::::::::::: 88.8:38.8 8xx. 8:::::: ::::::::: :::: 8: 8xxxx 88: :::: 88: : ::::: *:::::: *:::: 3. 8 ::::::: 8xxixe: :::::: 8:8 88: 3:3: 38.3: $ 8.8.x: screens is is {.{x: 3.88:: xxx: 8x8s $3.8: ::::::: 8883:38:a:: 8xxx &:ixx::::::::xx 8.8; 8.88. :::::::::::: Patent Application Publication Nov. 29, 2012 Sheet 58 of 79 US 2012/0301400 A1 figure { tiphenylaiarie, position 3 K.
Load more

Recommended publications
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • I Regulations
    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,669,108 B2 Williams Et Al
    USOO9669.108B2 (12) United States Patent (10) Patent No.: US 9,669,108 B2 Williams et al. (45) Date of Patent: Jun. 6, 2017 (54) MEDITOPES AND MEDITOPE-BINDING (56) References Cited ANTIBODIES AND USES THEREOF U.S. PATENT DOCUMENTS (71) Applicant: City of Hope, Duarte, CA (US) 7.754,853 B2 7/2010 Hellendoorn et al. 8,592,149 B2 11/2013 Ramakrishnan (72) Inventors: John C. Williams, Monrovia, CA (US); 8,658,774 B2 2/2014 Williams et al. David A. Horne, Duarte, CA (US); 2004/0001842 A1 1/2004 Michaeli ............ A61K 39,0005 Yuelong Ma, Duarte, CA (US); Heng 2004, OO67503 A1 4, 2004 Tan et all 424,185.1 Wei Chang, Foster City, CA (US); 2005, OO42664 A1 2/2005 Wua etC al.a. Joshua M. Donaldson, Lumberton, NJ 2005, OO69549 A1 3/2005 Herman (US); Cindy Zer, Duarte, CA (US); 2005/026O711 A1 11/2005 Datta et al. Krzysztof Bzymek, Pasadena, CA 2008, OO38260 A1 2/2008 Ponath et al. (US); Kendra N. Avery Pasadena, CA 39925. A 299 ElC a (US); Jun Xie, Duarte, CA (US) 2009/0202568 A1 8/2009 Eriksson et al. 2010.0068135 A1 3/2010 Rock (73) Assignee: City of Hope,s Duarte,s CA (US) 2010/0076178 A1 3/2010 Ghayur et al. (*) Notice: Subject to any disclaimer, the term of this FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. WO WO-96.40210 12/1996 WO WOO 132207 A1 * 5, 2001 ........ A61K 39,385 WO WO-O2/O72832 9, 2002 (21) Appl.
    [Show full text]
  • CUSTOMS TARIFF - SCHEDULE 99 - I
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2016 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • INN Working Document 05.179 Update 2011
    INN Working Document 05.179 Update 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Patent Application Publication Oo) Pub. No.: US 2012/0301400 Al Williams Et Al
    US 20120301400A1 US 20120301400A1 (19) United States (12) Patent Application Publication oo) Pub. No.: US 2012/0301400 Al Williams et al. (43) Pub. Date: Nov. 29,2012 (54) MEDITOPES AND MEDITOPE-BINDING (30) Foreign Application Priority Data ANTIBODIES AND USES THEREOF Oct. 10, 2011 (US) ................. PCT/US2011/055656 (76) Inventors: John C. Williams, Monrovia, CA (US); David A. Horne, Duarte, CA Publication Classification (US); Yuelong Ma, Duarte, CA (51) Int. Cl. (US); Heng Wei Chang, Foster C07K16/18 (2006.01) City, CA (US); Joshua Michael C07K 7/08 (2006.01) Donaldson, Lumberton, NJ (US); C07K1/14 (2006.01) Cindy Zer, Duarte, CA (US); A61K 39/395 (2006.01) Krzysztof Bzymek, Pasadena, CA A61K 49/00 (2006.01) (US); Kendra Nicole Avery, C12N 5/071 (2010.01) Pasadena, CA (US); Jun Xie, C07K 7/06 (2006.01) Duarte, CA (US) C07K2/00 (2006.01) (21) Appl. No.: 13/443,804 (52) U.S. Cl......... 424/9.1; 530/387.9; 530/330; 530/329; 530/328; 530/327; 530/326; 530/321; 424/139.1; (22) Filed: Apr. 10, 2012 424/178.1; 435/331 Related U.S. Application Data (57) ABSTRACT (63) Continuation-in-part of application No. 13/270,207, Antibodies and meditopes that bind to the antibodies are filed on Oct. 10, 2011. provided, as well as complexes, compositions and combina­ (60) Provisional application No. 61/391,558, filed on Oct. tions containing the meditopes and antibodies, and methods 8, 2010, provisional application No. 61/597,708, filed of producing, using, testing, and screening the same, includ­ on Feb.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0166697 A1 Bender (43) Pub
    US 2016O166697A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0166697 A1 Bender (43) Pub. Date: Jun. 16, 2016 (54) METHOD OF TREATING CANCER A619/00 (2006.01) A647/4 (2006.01) (71) Applicant: Intensity Therapeutics, Inc., Westport, A647/8 (2006.01) CT (US) A6II 45/06 (2006.01) A619/08 (2006.01) (72) Inventor: Lewis H. Bender, Redding, CT (US) A 6LX3/555 (2006.01) (52) U.S. Cl. (21) Appl. No.: 15/052,326 CPC. A61K47/12 (2013.01); A61 K9/08 (2013.01); 1-1. A61K 33/24 (2013.01); A61 K3I/555 (22) Filed: Feb. 24, 2016 (2013.01); A61 K47/14 (2013.01); A61K47/18 Related U.S. Application Data (2013.01); A61K 45/06 (2013.01); also (63) Continuation of application No. 14/280,036, filed on May 16, 2014, which is a continuation of application (57) ABSTRACT No. PCT/US2013/059841, filed on Sep. 15, 2013. The invention provides a method for treating cancer using a (60) Provisional application No. 61/779,509, filed on Mar. coadministration strategy that combines local codelivery of a 13, 2013, provisional application No. 61/707,733, therapeutic agent and an intracellular penetration enhancing filed on Sep. 28, 2012, provisional application No. agent, and optionally in further combination with local 61/703,890, filed on Sep. 21, 2012. administration of an immunotherapeutic agent, such as a cancer vaccine or NKTagonist. The invention also provides a Publication Classification method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to Sub (51) Int.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
    INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 15/06/2006 INTERNATIONAL NONPROPRIETARY NAMES (INN) FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES (A REVIEW) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines (QSM) Medicines Policy and Standards (PSM) Department CONTENTS 0. INTRODUCTION…………………………………….........................................................................................v 1. PHARMACOLOGICAL CLASSIFICATION OF BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES……………………………………................................1 2. CURRENT STATUS OF EXISTING STEMS OR SYSTEMS FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES…………………….3 2.1 Groups with respective stems ……………………………………………………………………3 2.2 Groups with respective pre-stems………………………………………………………………4 2.3 Groups with INN schemes………………………………………………………………………….4 2.4 Groups without respective stems / pre-stems and without INN schemes…..4 3. GENERAL POLICIES FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES……………………………………………………………………………………………………...5 3.1 General policies for blood products……………………………………………………………5 3.2 General policies for fusion proteins……………………………………………………………5 3.3 General policies for gene therapy products………………………………………………..5 3.4 General policies for glycosylated and non-glycosylated compounds………...6 3.5 General policies for immunoglobulins……………………………………………………….7 3.6 General polices for monoclonal antibodies………………………………………………..7 3.7 General polices for skin substitutes……………………………………………………………9 3.8 General policies for transgenic products……………………………………………………9
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]